Humanized and chimeric N-terminal amyloid beta-antibodies

• US 6,750,324 B1
• Filed: 11/28/2000
• Issued: 06/15/2004
• Est. Priority Date: 12/02/1997
• Status: Expired due to Term

• Current Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson)
• Original Assignee: Neuralab Ltd. (Perrigo Company PLC)
• Inventors: Yednock, Theodore, Bard, Frederique, Schenk, Dale B.
• Primary Examiner(s): Kunz, Gary
• Assistant Examiner(s): NICHOLS, CHRISTOPHER J
• Application Number:
  US09/724,552
• Time in Patent Office: 1,295 Days
• Field of Search: 530/300, 530/350, 530/387.1, 424/130.1
• US Class Current: 530/387.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 2039/6037 Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
• CPC Class Codes: A61K 2039/605 MHC molecules or ligands thereof
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0007 Nervous system antigens; Prions
• CPC Class Codes: C07K 14/4711 Alzheimer's disease; Amyloid plaque core protein
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/77 Internalization into the cell
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: G01N 2800/2821 Alzheimer

Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit The methods are useful for prophylactic and therapeutic treatment of Alzheimer'"'"'s disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same.

Claims

1. A pharmaceutical composition comprising a chimeric or humanized antibody that specifically binds to an epitope within residues 1-10 of Aβ

and a pharmaceutical carrier.

2. The pharmaceutical composition of claim 1, wherein the antibody specifically binds to an epitope within residues 1-6 of Aβ

.

3. The pharmaceutical composition of claim 1, wherein the antibody specifically binds to an epitope within residues 1-5 of Aβ

.

4. The pharmaceutical composition of claim 1, wherein the antibody specifically binds to an epitope within residues 1-4 of Aβ

.

5. The pharmaceutical composition of claim 1, which is a sustained release composition.

6. The pharmaceutical composition of claim 1, wherein the isotype of the antibody is human IgG1.

7. The pharmaceutical composition of claim 1, wherein the carrier is a physiologically acceptable diluent for parenteral administration.

8. A diagnostic kit, comprising a chimeric or humanized antibody that specifically binds to an epitope within residues 1-10 of Aβ

.

9. The diagnostic kit of claim 8, wherein the antibody binds to an epitope within residues 4-10 of Aβ

.

10. The diagnostic kit of claim 8, wherein the antibody binds to an epitope within residues 8-10 of Aβ

.

11. The diagnostic kit of claim 8, wherein the antibody is labeled.

12. The diagnostic kit of claim 8, wherein the antibody is labeled with a paramagnetic label.